Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, today announced the company has appointed Alexander ‘Sandy’ Macrae, M.
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, presented new preclinical data from the Company’s proprietary In Vivo Protein Replacement Platform™ …
The biotech sector has had a really cruel start to the year. The Nasdaq Biotechnology Index (IBB) is down 26% so far in …
Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, today reported its fourth quarter and full year 2015 financial results and accomplishments.
Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, announced that the U.
Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the Company’s ongoing …
Analysts weighed in today on the coffee giant Keurig Green Mountain Inc (NASDAQ:GMCR) and biotechnology company Sangamo Biosciences, Inc. (NASDAQ:SGMO), as news of buyout deal that …
Liana Moussatos of Wedbush rates stocks in the biotechnology sector and is one of the top 50 analysts rated on TipRanks. Today, Moussatos reiterated ratings for …
In light of developments from the FDA, analysts remain bullish on both Relypsa Inc (NASDAQ:RLYP) and Sangamo Biosciences, Inc. (NASDAQ:SGMO).
Sangamo BioSciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, announced that the U.
